• No Comments

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. Open. Download Table | Schema for CALGB trial CALGB trial schema from publication: Small Cell Lung Cancer: Have We Made Any Progress Over the . This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage .

Author: Zule Nill
Country: Montenegro
Language: English (Spanish)
Genre: Art
Published (Last): 1 December 2014
Pages: 481
PDF File Size: 20.74 Mb
ePub File Size: 18.8 Mb
ISBN: 340-5-15812-727-4
Downloads: 97458
Price: Free* [*Free Regsitration Required]
Uploader: Akinomuro

All analyses were done on an intention-to-treat basis.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

No statistically significant differences between the two groups were reported for the rates of progression-free survival or local or metastatic disease progression. The study enrolled patients with histologically or cytologically proven SCLC recruited from 3610 centers in 7 European countries and Canada between and In this trial, survival was higher than previously reported in other trials of this patient population, and radiation toxicities were lower than expected.


By Alice Goodman June 25, Advertisement. Updated Trial Findings View More. An international randomised trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited calb small cell lung cancer and good performance status.

It evaluated the optimization of chemoradiotherapy in limited-stage SCLC. It was challenging to accrue patients with this disease.

Radiation-related toxicities were lower than expected likely due to 306100 use of modern RT techniques These inconclusive results suggest that either schedule can be used in this setting. Taofeek Kunle Owonikoko, MD. Adverse events were not significantly different between the two groups as well, with the exception of more neutropenia in patients treated with twice-daily radiation therapy.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

Clinical Applications of Genomic Studies R. Seidman, MD, and Charles E. High-dose radiation therapy to the lungs and esophagus in the once-daily arm did not seem to translate to a significant difference between the arms in terms of esophagitis or pneumonitis.


Median overall survival was 30 months vs 25 months, a difference that is not statistically significant. Eighty percent of patients had stage III disease. A total of 25 patients in the twice-daily radiation therapy group and 32 in the once-daily radiation therapy group did not get concurrent chemoradiation therapy. Formal discussant Taofeek Kunle Owonikoko, MDof Winship Cancer Institute of Emory University, Atlanta, said it has been controversial whether to use once-daily or twice-daily radiation therapy in this patient population.

There was one death in the twice-daily group and two calhb the once-daily group due to radiation pneumonitis. Survival in both arms was higher than previously reported. Patients with any response were offered prophylactic cranial radiation therapy. Expert Point of View: There was no statistically significant overall survival difference between the groups.